Loading clinical trials...
Loading clinical trials...
A Unicentric, Randomized, Open-label, Cross-over Clinical Trial to Assess the Effect of Dapagliflozin, Spironolactone and Their Combination, When Added to Renin-Angiotensin System Blockade, on Lowering Urine Albumin-to-Creatinine Ratio in Adult Patients with Alport Syndrome
Conditions
Interventions
Treatment with Spironolactone followed by Dapagliflozin followed by their combination
Treatment with Dapagliflozin followed by Spironolactone followed by their combination
Locations
1
Romania
Fundeni Clinical Institute
Bucharest, Sector 2, Romania
Start Date
February 26, 2024
Primary Completion Date
December 1, 2025
Completion Date
March 1, 2026
Last Updated
July 15, 2024
NCT06065852
NCT04947813
NCT06226896
NCT00481130
NCT02136862
NCT00622544
Lead Sponsor
Stefan Lujinschi
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions